Healthcare / Medical DevicesKOSDAQ
$818.00
-34.00 (-3.99%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-2.4B · quality 71.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$41.3B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-23.1%
↓Gross Margin
46.9%
↓Debt/Equity
0.34
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-15.1%
FCF CAGR
—
FCF margin
-15.2%
FCF / Net income
0.20x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $16.05B · net income $-12.30B · FCF $-2.44B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $16.05B | $16.05B | $17.27B | $26.61B | $26.20B |
| Net Income | $-12.30B | $-12.30B | $-951.4M | $-4.96B | $-9.62B |
| EBITDA | $-5.35B | $-5.35B | $3.14B | $446.1M | $-4.40B |
| EPS | -248.00 | -248.00 | -23.00 | -205.00 | -500.00 |
| Gross Margin | 46.9% | 46.9% | 37.2% | 30.6% | 28.6% |
| Operating Margin | -18.1% | -18.1% | -19.7% | -6.7% | -28.8% |
| Net Margin | -76.6% | -76.6% | -5.5% | -18.6% | -36.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.34 | 0.34 | 0.62 | 0.87 | 4.47 |
| Current Ratio | 2.20 | 2.20 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.44B | $-2.44B | $-1.46B | $-4.88B | $-6.09B |
| Returns | |||||
| ROE | -23.1% | -23.1% | -2.4% | -17.2% | -148.4% |
| Valuation | |||||
| EV/EBITDA | — | — | 12.52 | 83.59 | — |
| P/B | 0.76 | 0.76 | 0.96 | 1.03 | 4.50 |
| Growth & Yield | |||||
| Revenue Growth | -7.1% | -7.1% | -35.1% | 1.6% | — |
| EPS Growth | -978.3% | -978.3% | 88.8% | 59.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-5.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-23.00 → -248.00
Residual
-5.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.